Gregory J. McKenzie

Gregory J McKenzie has worked in the biotechnology industry since 2013. In that time, they have held positions at Prolacta Bioscience, Pareto Bio, Inc., and Seres Therapeutics. From 2019 to present, they have been the Vice President of Product Innovation at Prolacta Bioscience, where they work to discover, develop, and deliver life-changing solutions for critically ill babies and other vulnerable patients. From 2017 to 2019, they were the Vice President of Research & Chief Scientific Officer at Pareto Bio, Inc., where they worked to develop therapies based on microbes and microbial products to prevent and treat human diseases. From 2013 to 2017, they were the Senior Principal Scientist at Seres Therapeutics, where they were a key member of the SER-109 development team, a novel microbiome therapeutic for treatment of recurrent Clostridioides difficile. Gregory J was also involved in proof-of-concept, pre-clinical, phase I & phase II development and tech transfer, and developed drug product process for phase I SER-262 and SER-287.

Gregory J McKenzie completed a Post-doctoral Fellowship at the Johns Hopkins University School of Medicine in Molecular Biology & Genetics. Gregory J then obtained a Ph.D. from Baylor College of Medicine in Molecular & Human Genetics. Prior to that, they earned a B.Sc. with First Class Honors in Cell Biotechnology from the University of Alberta.